Yervoy (ipilimumab) is a CTLA-4-blocking monoclonal antibody immunotherapy used across multiple advanced malignancies, both as monotherapy and in combination regimens (commonly with nivolumab). Its U.S. oncology indications include melanoma, renal cell carcinoma combinations, MSI-H/dMMR metastatic colorectal cancer combinations, hepatocellular carcinoma combinations, NSCLC combinations, mesothelioma combinations, and selected esophageal cancer settings. U.S. initial approval was in 2011.
Bristol Myers Squibb said 2025 revenue was flat as a 17% increase in growth-portfolio sales offset a 15% decline in legacy drugs. The company expects legacy sales to fall another 12-16% in 2026, with newer products such as Opdivo, Reblozyl and Breyanzi supporting results.
A Feb. 20, 2026 study in the Journal of Experimental Medicine identified CD8 T cell-derived TNF and TNFR2 signaling as drivers of ICI-related myocarditis in mice. Blocking TNFR2 prevented the inflammatory cycle in the heart.
Scientists at Cincinnati Children's have identified a molecular pathway responsible for immune checkpoint inhibitor-induced myocarditis and demonstrated that blocking TNF signaling can prevent this fatal complication without compromising anti-tumor efficacy.
Decreases in circulating tumor DNA within 3-4 weeks of immune checkpoint inhibitor therapy were strongly associated with higher response rates and longer survival in patients with unresectable stage III/IV melanoma, according to a multi-institutional retrospective analysis.
Healthcare sector surged 10% since Q4 2025, outpacing all S&P 500 sectors as investors rotate from tech to pharmaceutical value plays. Major drugmakers demonstrate resilience following Medicare price negotiations implementation.
Bristol Myers Squibb's growth portfolio increased 17% in 2025, partially offsetting a 15% decline in legacy products facing generic competition. The company's stock gained 11.4% in the past month on strong fourth-quarter results.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07176650 |
Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular Carcinoma |
RECRUITING | PHASE1 |
| NCT05004025 |
Single Arm Trial of Tumor-Treating Fields in Combination With Nivolumab and Ipilimumab in Metastatic Uveal Melanoma |
COMPLETED | PHASE1 |
| NCT03029780 |
An Investigational Immuno-Therapy Safety and Efficacy Study of Multiple Administration Regimens for Nivolumab Plus Ipilimumab in Subjects With Renal Cell Carcinoma |
COMPLETED | PHASE2 |
| NCT02854488 |
Yervoy Pregnancy Surveillance Study |
WITHDRAWN | |
| NCT01496807 |
Yervoy With Sylatron Unresectable Stage 3 or 4 Melanoma |
COMPLETED | PHASE1 |
